Nephrostomies in obstructive uropathy; how should hormone resistant prostate cancer patients be managed and can we predict who will benefit?

被引：0
|
作者：
M R E Harris
M J Speakman
机构：
[1] Taunton and Somerset NHS Trust,
[2] Musgrove Park Hospital,undefined
来源：
Prostate Cancer and Prostatic Diseases | 2006年 / 9卷
关键词：
nephrostomy; hormone; obstructive uropathy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Current opinion advocates the use of nephrostomies in hormone naive patients with obstructive uropathy while hormone resistant patients require an individual approach. Patients undergoing a nephrostomy for uropathy were retrospectively analysed, with particular interest in hormone status and blood levels. Over a 46-month period, 26/112 nephrostomies were performed for prostate cancer induced uropathy. Survival was 226.5 days for hormone naive patients, 114.3 days in the responsive group and 100.2 days if resistant. Bilateral cases survived 72.1 days versus 157.6 days for unilateral patients. All patients should be considered for nephrostomy despite their hormone status.
引用
收藏
页码：42 / 44
页数：2
相关论文
共 50 条
  • [31] How should we treat castration-resistant prostate cancer patients who have received androgen deprivation therapy (ADT) plus docetaxel upfront for hormone-sensitive diseae? Mature analysis of the GETUG-AFU 15 phase III trial
    Lavaud, P.
    Gravis, G.
    Legoupil, C.
    Foulon, S.
    Joly, F.
    Oudard, S.
    Priou, F.
    Soulie, M.
    Mourey, L.
    Latorzeff, I.
    Delva, R.
    Krakowski, I.
    Laguerre, B.
    Theodore, C.
    Ferrero, J-M.
    Beuzeboc, P.
    Habibian, M.
    Boher, J. M.
    Tergemina-Clain, G.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [32] Baseline low serum dehydroepiandrosterone sulfate can predict poor responsiveness to hormone therapy in patients with hormone-naive prostate cancer with skeletal metastases
    Yano, Akihiro
    Kagawa, Makoto
    Takeshita, Hideki
    Okada, Yohei
    Morozumi, Makoto
    Kawakami, Satoru
    INTERNATIONAL JOURNAL OF UROLOGY, 2017, 24 (12) : 861 - 862
  • [33] How can we better identify patients with rectal bleeding who are at high risk of colorectal cancer? An observational study
    Kieran Purich
    Yiling Zhou
    Shawn Dodd
    Yan Yuan
    Jonathan White
    International Journal of Colorectal Disease, 2022, 37 : 573 - 582
  • [34] How can we better identify patients with rectal bleeding who are at high risk of colorectal cancer? An observational study
    Purich, Kieran
    Zhou, Yiling
    Dodd, Shawn
    Yuan, Yan
    White, Jonathan
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2022, 37 (03) : 573 - 582
  • [35] CAN WE USE PREOPERATIVE PSA KINETICS TO PREDICT PATHOLOGIC UPGRADING IN CONTEMPORARY PATIENTS DIAGNOSED WITH GLEASON 6 PROSTATE CANCER?
    Krane, Louis S.
    Kaul, Sanjeev
    Siddiqui, Sameer
    Bhandari, Mahendra
    Peabody, James O.
    Menon, Mani
    JOURNAL OF UROLOGY, 2009, 181 (04): : 55 - 55
  • [36] How long should we follow patients managed for muscle-invasive bladder cancer? Lesson learned from a recent clinical practice
    De Rose, Aldo Franco
    Vecco, Francesco
    Ambrosini, Francesca
    Malinaric, Rafaela
    Mantica, Guglielmo
    Terrone, Carlo
    ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA, 2022, 94 (03) : 369 - 370
  • [37] How can we make cancer survival statistics more useful for patients and clinicians: An illustration using localized prostate cancer in Sweden
    Sandra Eloranta
    Jan Adolfsson
    Paul C. Lambert
    Pär Stattin
    Olof Akre
    Therese M-L. Andersson
    Paul W. Dickman
    Cancer Causes & Control, 2013, 24 : 505 - 515
  • [38] How can we make cancer survival statistics more useful for patients and clinicians: An illustration using localized prostate cancer in Sweden
    Eloranta, Sandra
    Adolfsson, Jan
    Lambert, Paul C.
    Stattin, Par
    Akre, Olof
    Andersson, Therese M-L.
    Dickman, Paul W.
    CANCER CAUSES & CONTROL, 2013, 24 (03) : 505 - 515
  • [39] Use of "intracrine androgen signaling signature" to predict benefit from abiraterone acetate (AA) in patients with castrate-resistant prostate cancer (CRPC)
    Efstathiou, E.
    Tu, S.
    Aparicio, A.
    Hoang, A.
    Wen, S.
    Troncoso, P.
    Smith, L. A.
    Chieffo, N.
    Molina, A.
    Logothetis, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Is Metastatic Prostate Cancer Changing, and How Will We Know It? It's Time for Standard Nomenclature for Nonosseous Metastases in Clinical Trials of Patients with Metastatic Castration Resistant Prostate Cancer
    Tsao, Che-Kai
    Galsky, Matthew D.
    Oh, William K.
    EUROPEAN UROLOGY, 2014, 66 (02) : 184 - 185
12345